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Background: Indomethacin (IND) is used in preterm infants for prophylaxis against
intraventricular hemorrhage. It has a highly variable exposure between patients, with a risk of
subtherapeutic or toxic levels from current dosing guidelines.
Objectives/Goal: The objective of this study was to measure IND concentrations in preterm
infants and determine how patient characteristics are related to exposure.
Methods/Design: This was prospective cohort study of preterm infants enrolled at birth (n=10).
They received intravenous IND administered in 3 doses of 0.1mg/kg over 96 hrs. Systemic IND was
measured by plasma and dried blood spot. Urine samples were measured for IND and metabolites.
Pearson correlation analysis was performed between IND AUC 0-96 hours, patient characteristics,
and excretion endpoints.
Results: Results showed that IND AUC0-96 hrs had a significant correlation with patient birthweight
(BW) (r=0.76, p=0.01), as well as significant correlation between BW and percent drug recovered
as unchanged IND in urine (r=0.72, p=0.02).

Conclusions: Current dosing regimens show higher levels of IND exposure for higher BW patients.
The correlation between unchanged IND in urine and BW suggests that delayed metabolism of IND
may contribute to the increased exposure. These results show that current IND dosing regimens
are not achieving comparable exposure in preterm infants.

